130 related articles for article (PubMed ID: 1580821)
21. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
22. An analysis of treatment options and outcome in patients with Parkinson's disease and severe dyskinesias.
Mark MH; Sage JI
Ann Clin Lab Sci; 1994; 24(1):12-21. PubMed ID: 8147565
[TBL] [Abstract][Full Text] [Related]
23. Effect of MK-458 (HPMC) in Parkinson's disease previously untreated with dopaminergic drugs. A double-blind, placebo-controlled multicenter study.
Koller WC; Block GA; Ahlskog JE; Ahrens S; Cedarbaum JM; Cyhan G; Goetz CG; LeWitt PA; Liss C; McLean L
Clin Neuropharmacol; 1991 Aug; 14(4):322-9. PubMed ID: 1913699
[TBL] [Abstract][Full Text] [Related]
24. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
[TBL] [Abstract][Full Text] [Related]
25. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
26. Pergolide mesylate: four years experience in Parkinson's disease.
Tanner CM; Goetz CG; Glantz RH; Klawans HL
Adv Neurol; 1987; 45():547-9. PubMed ID: 3825732
[No Abstract] [Full Text] [Related]
27. A crossover, controlled study comparing pergolide with bromocriptine as an adjunct to levodopa for the treatment of Parkinson's disease.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri V; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Neurology; 1995 Mar; 45(3 Suppl 3):S22-7. PubMed ID: 7715793
[TBL] [Abstract][Full Text] [Related]
28. Treatment of Parkinson's disease. From theory to practice.
Ahlskog JE
Postgrad Med; 1994 Apr; 95(5):52-4, 57-8, 61-4 passim. PubMed ID: 8153048
[TBL] [Abstract][Full Text] [Related]
29. Further studies with pergolide in Parkinson disease.
Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
[TBL] [Abstract][Full Text] [Related]
30. The variability of levodopa response in Parkinson's disease: is sensitization reversible?
Jabre MG; Bejjani BP
Mov Disord; 2008 Apr; 23(6):924; author reply 925. PubMed ID: 18163452
[No Abstract] [Full Text] [Related]
31. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J
Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of pergolide and mesulergine.
Lieberman AN; Gopinathan G; Neophytides A
Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
[TBL] [Abstract][Full Text] [Related]
33. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Schwarz J; Scheidtmann K; Trenkwalder C
Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
[TBL] [Abstract][Full Text] [Related]
34. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
35. An open label trial of pergolide in Thai patients with Parkinson's disease.
Poungvarin N; Prayoonwiwat N; Devahasatin V; Viriyavejakul A
J Med Assoc Thai; 1996 Apr; 79(4):205-9. PubMed ID: 8708504
[TBL] [Abstract][Full Text] [Related]
36. Pergolide and Parkinson's disease: new preparation. No clear benefit.
Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
[TBL] [Abstract][Full Text] [Related]
37. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
[TBL] [Abstract][Full Text] [Related]
38. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study.
Pezzoli G; Martignoni E; Pacchetti C; Angeleri VA; Lamberti P; Muratorio A; Bonuccelli U; De Mari M; Foschi N; Cossutta E
Mov Disord; 1994 Jul; 9(4):431-6. PubMed ID: 7969210
[TBL] [Abstract][Full Text] [Related]
39. Pergolide in the treatment of Parkinson's disease.
Mear JY; Barroche G; de Smet Y; Weber M; Lhermitte F; Agid Y
Neurology; 1984 Jul; 34(7):983-6. PubMed ID: 6539880
[TBL] [Abstract][Full Text] [Related]
40. Controlled-release levodopa/carbidopa. I. Sinemet CR3 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Breck L; Kutt H; McDowell FH
Neurology; 1987 Feb; 37(2):233-41. PubMed ID: 3808304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
